Is NKTR a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Nektar Therapeutics (NKTR) rests on Rezpegaldesleukin in atopic dermatitis: The lead program targets a large, competitive dermatology market. Q1 2026 revenue is ~$10.9M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Whether NKTR is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Nektar Therapeutics is a San Francisco based, Nasdaq-listed clinical-stage biopharmaceutical company whose pipeline is anchored by rezpegaldesleukin (rezpeg), a first-in-class biologic designed to stimulate and expand regulatory T cells to restore immune balance. Nektar regained full rights to the molecule from Eli Lilly and is developing it across immuno-dermatology indications, with a Phase 2b program in moderate-to-severe atopic dermatitis (REZOLVE-AD, 393 patients), a Phase 2b program in severe-to-very-severe alopecia areata (REZOLVE-AA), and a Phase 2 study in type 1 diabetes. In February 2026 the company reported maintenance data from REZOLVE-AD showing durable and new responses on key disease measures with both monthly and quarterly dosing, and rezpeg holds FDA Fast Track designation in atopic dermatitis. As a clinical-stage company, Nektar's income statement reflects development rather than commercial scale: Q1 2026 revenue was ~$10.9M (largely legacy royalties and collaboration-related items) against a net loss of ~$44.9M, with R&D the dominant expense. The business is funded by its balance sheet rather than product sales, and an April 2026 secondary offering lifted cash and investments to over ~$1B. Management has guided that pivotal Phase 3 trials in atopic dermatitis and alopecia areata would produce initial data readouts around 2028 with a potential BLA submission around 2029, which frames Nektar as a multi-year, catalyst-driven story rather than a near-term earnings play.
What's the case for buying NKTR?
Rezpegaldesleukin in atopic dermatitis
The lead program targets a large, competitive dermatology market. REZOLVE-AD Phase 2b maintenance data reported in February 2026 showed durable responses with both monthly and quarterly dosing, and the asset carries FDA Fast Track designation, setting up a planned Phase 3 program.
Alopecia areata expansion
REZOLVE-AA established Phase 2b proof-of-concept in severe-to-very-severe alopecia areata, giving rezpeg a second immuno-dermatology indication. Nektar plans to advance the molecule into Phase 3 in alopecia areata, broadening the addressable opportunity beyond a single disease.
Treg mechanism and broader pipeline
Rezpeg's regulatory T cell mechanism is being explored in type 1 diabetes as well, and Nektar retains earlier-stage assets including TNFR2 bispecific programs (NKTR-0165, NKTR-0166), NKTR-422, and IL-15 agonist NKTR-255, offering optionality if the Treg approach validates.
Strengthened balance sheet
An April 2026 financing pushed cash and investments to over ~$1B, extending runway to fund the planned pivotal trials. For a clinical-stage biopharma, capital adequacy through the next major readouts is a central input to whether programs reach their catalysts.
What are the risks to NKTR?
Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Rezpegaldesleukin's pivotal outcomes are binary and years away (initial Phase 3 readouts guided around 2028), and clinical or regulatory setbacks could sharply affect the shares. The atopic dermatitis and alopecia areata markets are crowded with established biologics such as Dupixent and JAK inhibitors, so commercial success is not assured even with a positive trial. Additional capital raises could dilute existing holders, and the stock has historically been volatile around data and trial news.
How is NKTR valued? (as of July 2026)
Snapshot for NKTR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Share price: ~$74 (early July 2026)
- Market cap: ~$2.5B
- Q1 2026 revenue: ~$10.9M
- Q1 2026 net loss: ~$44.9M (~$1.82/share)
- Q1 2026 R&D expense: ~$35.7M
- Cash and investments: ~$1B (after April 2026 financing)
As a clinical-stage biopharma, Nektar carries no meaningful earnings, so traditional profit multiples do not apply and its value reflects the perceived probability and size of rezpegaldesleukin's opportunity. The ~$1B cash position is a large fraction of the ~$2.5B market cap, meaning much of the equity value is tied to pipeline expectations rather than current operations.
How do you decide if NKTR is a buy?
Rather than asking whether NKTR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NKTR indirectly through an index or sector ETF before adding more.
For the full picture, see the NKTR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NKTR against your real portfolio and see your actual exposure before deciding.
The bottom line on NKTR
The bottom line: Nektar Therapeutics's story right now is Rezpegaldesleukin in atopic dermatitis, with q1 2026 revenue at ~$10.9M. If you believe that narrative continues, the call is about sizing NKTR sensibly and checking overlap with what you own; if you doubt it (the risk: nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around NKTR with Walnut
Use Nektar Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NKTR a good stock to buy right now?
+
The case for Nektar Therapeutics right now is Rezpegaldesleukin in atopic dermatitis, with q1 2026 revenue at ~$10.9M. If you believe that thesis holds, NKTR is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Nektar Therapeutics do?
+
Nektar Therapeutics is a San Francisco based, Nasdaq-listed clinical-stage biopharmaceutical company whose pipeline is anchored by rezpegaldesleukin (rezpeg), a first-in-class biol
What are the main risks of NKTR?
+
Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Rezpegaldesleukin's pivotal outcomes are binary and years away (initial Phase 3 readouts guided around 2028), and clinical or regulatory setbacks could sharply affect the shares. The atopic dermatitis and alopecia areata markets are crowded with established biologics such as Dupixent and JAK inhibitors, so commercial success is not assured even with a positive trial. Additional capital raises could dilute existing holders, and the stock has historically been volatile around data and trial news.
What does Nektar Therapeutics do?
+
Nektar is a clinical-stage biopharmaceutical company developing rezpegaldesleukin, a first-in-class biologic that stimulates regulatory T cells to help restore immune balance. It is being studied in immune and inflammatory conditions including atopic dermatitis, alopecia areata, and type 1 diabetes.
Is NKTR profitable?
+
No. As a clinical-stage company, Nektar has no approved product revenue and runs operating losses while it funds trials. In Q1 2026 it reported ~$10.9M of revenue and a net loss of ~$44.9M. Low, volatile revenue is normal for this category rather than a red flag.
What is rezpegaldesleukin?
+
Rezpegaldesleukin (rezpeg) is Nektar's lead drug candidate, a regulatory T cell stimulator designed to expand Tregs and dampen harmful immune activity. Nektar regained full rights to it from Eli Lilly and is advancing it toward Phase 3 in atopic dermatitis and alopecia areata.
How much cash does Nektar have?
+
Nektar reported ~$731.6M in cash and investments at the end of Q1 2026, and an April 2026 secondary offering raised additional capital that lifted the total to over ~$1B. That funding is intended to support its planned pivotal trials.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NKTR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.